Osimertinib Versus First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Metastatic EGFR-Mutant Non–Small Cell Lung Cancer: A Target Trial Emulation Study of Real-World Survival and Safety Outcomes
In this large real-world comparative effectiveness study using target trial emulation, first-line osimertinib was associated with substantially prolonged OS and a favorable safety profile, including lower rates of severe infections and hospitalizations, compared with first-generation EGFR-TKIs in patients with metastatic EGFR-mutant NSCLC.
Authors
- Ren‐Hua Ye (ORCID: https://orcid.org/0000-0003-2418-7829)
- Po‐Huang Chen (ORCID: https://orcid.org/0000-0002-0280-6417)
- Hsin‐Yu Chen (ORCID: https://orcid.org/0000-0002-2765-1685)
- Ming-Shen Dai (ORCID: https://orcid.org/0000-0002-3953-5243)
- Ching‐Liang Ho (ORCID: https://orcid.org/0000-0002-8378-1687)
- Cho‐Hao Lee (ORCID: https://orcid.org/0000-0002-6061-5168)
- Li‐Ting Kao (ORCID: https://orcid.org/0000-0003-0692-7408)
- Hong‐Jie Jhou (ORCID: https://orcid.org/0000-0003-3304-4643)
- Tina Yi Jin Hsieh (ORCID: https://orcid.org/0000-0001-6296-0689)
- Xiaoyi Zhang (ORCID: https://orcid.org/0000-0001-5124-4919)
- Yuhan Chen (ORCID: https://orcid.org/0000-0001-9170-7439)
Institutions
- Tri-Service General Hospital (TW)
- Albert Einstein College of Medicine (US)
- Beth Israel Deaconess Medical Center (US)
- Englewood Hospital and Medical Center (US)
- Jacobi Medical Center (US)
- Taipei Tzu Chi Hospital (TW)
- Chi Mei Medical Center (TW)
- Changhua Christian Hospital (TW)
- National Defense Medical Center (TW)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1200/op-25-00788
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00